ADC Therapeutics SA logo
ADC Therapeutics SA ADCT
$ 1.23 8.85%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

ADC Therapeutics SA Financial Statements 2025-2011 | ADCT

Annual Financial Statements ADC Therapeutics SA

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

139 M 106 M 89.1 M 107 M 1.22 B 2.19 B - - - - - - - - -

Shares

127 M 97.2 M 81.7 M 78.2 M 76.7 M 76.7 M - - - - - - - - -

Historical Prices

1.09 1.09 1.09 1.37 15.9 28.6 - - - - - - - - -

Net Income

-143 M -158 M -240 M -157 M -230 M -246 M -116 M -123 M -89.9 M - - - - - -

Revenue

81.4 M 70.8 M 69.6 M 210 M - - 2.34 M 1.14 M 1.8 M - - - - - -

Cost of Revenue

5.8 M 5.95 M 2.53 M 3.3 M 1.39 M - - - - - - - - - -

Operating Income

-121 M -131 M -166 M -123 M -262 M -219 M -119 M -126 M - - - - - - -

Interest Expense

22.7 M 50.2 M 46.3 M 36.7 M - - - - - - - - - - -

EBITDA

-121 M -129 M -165 M -122 M -262 M -219 M -119 M -126 M -91.5 M - - - - - -

Operating Expenses

- - - 334 M 296 M 219 M 122 M 127 M - - - - - - -

General and Administrative Expenses

36.6 M 41.9 M 48.4 M 74.4 M 71.5 M 55.1 M 13.8 M 8.6 M 7.81 M - - - - - -

All numbers in USD currency

Quarterly Income Statement ADC Therapeutics SA

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

114 M 154 M - 136 M 114 M 107 M - 105 M 95.7 M 82.6 M - 82.3 M 81.5 M 80.8 M - - - 76.8 M - 76.7 M 76.7 M 76.7 M - 70.9 M 62.9 M 51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-56.6 M -33 M - -41 M -56.6 M -38.6 M - -44 M -36.5 M -46.6 M - -47.8 M -47.1 M -59.4 M - - - -16.7 M - -71.5 M -72.6 M -51.5 M - -20.3 M -127 M -43.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

18.1 M 20.9 M - 16.4 M 18.8 M 23 M - 18.5 M 17.4 M 18.1 M - - - - - - - - - 13.1 M 3.76 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - 366 K 1.32 M 590 K - - - 529 K - 502 K 121 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-44.1 M -25.2 M - -31 M -44.1 M -28.5 M - -35.6 M -29 M -33.6 M - -37.4 M -39.8 M -51.6 M - - - -40.4 M - -57.8 M -70.5 M -70.7 M - -52.4 M -44.9 M -43.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-182 K 2.63 M - 925 K -182 K 12.2 M - 13.1 M 12.7 M 12.5 M - -10.5 M -13.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-44.1 M -25.2 M - -31 M -43.8 M -28.1 M - -35.2 M -28.7 M -33.3 M - -37.4 M -39.8 M -51.6 M - - - -40.4 M - -57.8 M -70.5 M -70.7 M - -52.4 M -44.9 M -43.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - 51.9 M 59.1 M 70.6 M - - - 86.9 M - 70.9 M 74.2 M 70.7 M - 52.4 M 44.9 M 43.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

8.82 M 9.9 M - 8.33 M 8.82 M 9.96 M - 10 M 10.2 M 12 M - 9.36 M 11.4 M 15.1 M - - - 19 M - 16.6 M 19.4 M 17.6 M - 14.2 M 15 M 5.88 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ADC Therapeutics SA ADCT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ADC Therapeutics SA plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Timber Pharmaceuticals Timber Pharmaceuticals
TMBR
- - $ 717 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA